Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study.

jueves, 31 de julio de 2025, 8:36 am ET1 min de lectura
OTLK--
Outlook Therapeutics, Inc. rose 1.95% in premarket trading. The company's stock price movement is not directly related to the given news events, as none of the news items pertain to Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios